Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials

MLA

Samuel Seidu, et al. “Aspirin Has Potential Benefits for Primary Prevention of Cardiovascular Outcomes in Diabetes: Updated Literature-Based and Individual Participant Data Meta-Analyses of Randomized Controlled Trials.” Cardiovascular Diabetology, vol. 18, no. 1, June 2019, pp. 1–15. EBSCOhost, https://doi.org/10.1186/s12933-019-0875-4.

APA

Samuel Seidu, Setor K. Kunutsor, Howard D. Sesso, J. M. Gaziano, J. E. Buring, Maria Carla Roncaglioni, & Kamlesh Khunti. (2019). Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovascular Diabetology, 18(1), 1–15. https://doi.org/10.1186/s12933-019-0875-4

Chicago

Samuel Seidu, Setor K. Kunutsor, Howard D. Sesso, J. M. Gaziano, J. E. Buring, Maria Carla Roncaglioni, and Kamlesh Khunti. 2019. “Aspirin Has Potential Benefits for Primary Prevention of Cardiovascular Outcomes in Diabetes: Updated Literature-Based and Individual Participant Data Meta-Analyses of Randomized Controlled Trials.” Cardiovascular Diabetology 18 (1): 1–15. doi:10.1186/s12933-019-0875-4.